Market Overview

Cellular Biomedicine Group Completes Patient Treatment for Phase I Clinical Trial for Liver Cancer

Share:
Related CBMG
Cellular Biomedicine's Stock Surges After Company Receives Strategic Investment
Cellular Biomedicine Group Names Tony Liu as CEO

Cellular Biomedicine Group (OTC: CBMG) is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.

The…Cellular Biomedicine Group (OTC: CBMG) is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.

The Phase I clinical trial for TC-DC therapy for HCC is an open-label clinical trial conducted with Shanghai's PLA 85 Hospital, one of China's largest Liver Disease Centers. The trial evaluated the safety and preliminary efficacy in lowering the incidence of tumor recurrence and metastasis by means of autologous immune cell therapy in primary HCC patients following standard tumor resection and TACE chemotherapy.

See full press release

Posted-In: News Guidance Offerings FDA Management Global

 

Related Articles (CBMG)

View Comments and Join the Discussion!